Additionally, receptor tyrosine kinase fusions (FGFR2 fusions in intrahepatic CCA) or variations (EGFR, BRAF, etc.)can also funnel into MEK/ERK activation [48]. The gene discussed is FGFR2; the disease is cholangiocarcinoma.